We Are Continuing To Conduct Preclinical Studies With Multiple 3ga Candidates In House And With Our Collaborators, With A Goal Of Advancing This Technology To Clinical Development.

People who have these conditions may be more prone to get uveitis: In some cases, doctors don’t know what causes non-infectious uveitis. After graduating from St. Your doctor may prescribe either eye drops or pills. There he was involved in research in radiation biology and received the husking Scholarship. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Genes can play an important role in uveitis. This injury, or trauma, may be caused by a blow or wound, eye surgery, a disease such as a virus, bacteria infection, or a parasite. Severe inflammation takes longer to clear up than mild inflammation does. Your doctor may order blood tests, X-rays, or other lab tests to check for medical conditions that might be linked with uveitis. http://www.theactproject.com/advisingeyesurgeon/2016/08/29/the-best-routes-for-speedy-plans-in-laser-eye-surgery/The disorder may affect only one eye.

This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. no dataIdera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Ideras proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

Leave a Reply

Your email address will not be published. Required fields are marked *